Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
| ▸ | KDM4A | O75164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3182485 | 0.88 | BRD4 (0.44) | L3MBTL1MAPTSMN1; SMN2KDM4EMEN1 | |
| SCHEMBL3175233 | 0.80 | ALDH1A1 (0.36) | L3MBTL1MAPTKDM4EKMT2AALDH1A1 | |
| SCHEMBL3175282 | 0.79 | L3MBTL1 (0.39) | L3MBTL1MAPTKDM4EMEN1KMT2A | |
| SCHEMBL3182695 | 0.77 | CASP3 (0.43) | L3MBTL1 | |
| SCHEMBL3166480 | 0.76 | L3MBTL1 (0.78) | L3MBTL1SMN1; SMN2KDM4EMEN1KMT2A | |
| SCHEMBL3175610 | 0.76 | NOTUM (0.46) | MAPTSMN1; SMN2KDM4EMEN1KMT2A | |
| SCHEMBL27766865 | 0.74 | ALDH1A1 (0.38) | L3MBTL1MAPTSMN1; SMN2KDM4EMEN1 | |
| SCHEMBL3182279 | 0.74 | L3MBTL1 (0.39) | L3MBTL1 | |
| SCHEMBL28807638 | 0.74 | SMN1; SMN2 (0.55) | L3MBTL1MAPTSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL4254704 | 0.73 | TSHR (0.44) | MAPTSMN1; SMN2KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016376-A1 | CASPASE INHIBITORS BASED ON PYRIDONE SCAFFOLD | LG LIFE SCIENCES LTD. (KR) | 2010-01-21 | — | — | US | disclosed |
| EP-2079698-A1 | CASPASE INHIBITORS BASED ON PYRIDAZINONE SCAFFOLD | LG Life Sciences Ltd. (KR) | 2009-07-22 | — | — | EP | disclosed |
| WO-2008056898-A1 | CASPASE INHIBITORS BASED ON PYRIDAZINONE SCAFFOLD | LG LIFE SCIENCES LTD. (KR) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016376-A1 | CASPASE INHIBITORS BASED ON PYRIDONE SCAFFOLD | CASP1, CASP5, CASP2 | L3MBTL1 1996/4885MAPT 1263/4885SMN1; SMN2 2012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.